Summary
Research published in Nature indicates that prior therapy, particularly with platinum-based chemotherapy, defines mutation profiles in childhood cancer at relapse. This treatment is associated with significant, rapidly detectable mutagenesis, tripling private signatures and doubling mutation burden, highlighting therapy-induced tumor evolution and opportunities for safer treatments.